Clinical Trial Update: Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant

View source ↗

Summary

This clinical trial update concerns the use of oral nilotinib for adults with chronic myeloid leukemia in blast crisis who are resistant or intolerant to imatin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia

Drugs mentioned

• Nilotinib (Tasigna) (nilotinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Myelogenous Leukemia | Status: NO_LONGER_AVAILABLE